Table 3.

Pooled percentile of clinical endpoints.

Subject Modality	No. of cohorts	No. of cases	Effect size % (95% CI)	RFA vs. ablative RT (p value)	Heterogeneity p	I2(%)
One-year LC rate (HCC and CRC mets)
All	32	3,687	87.2 (84.2–89.7)		<0.001	83.3
RFA	16	2,172	82.3 (77.2–86.4)		<0.001	80.0
RT	16	1,515	92.4 (89.2–94.7)	<0.001	<0.001	63.9
Two-year LC rate
All	28	2,549	84 (80.0–87.3)		<0.001	84.8
RFA	14	1,464	80.1 (72.7–85.8)		<0.001	88.2
RT	14	1,084	86.5 (81.7–90.2)	0.094	<0.001	66.4
Three-year LC rate
All	26	2,809	79.6 (74.9–83.6)		<0.001	87.4
RFA	13	1,649	75.7 (68.6–81.7)		<0.001	88.7
RT	13	1,160	83.9 (77.7–88.7)	0.062	<0.001	80.4
One-year OS (HCC)
All	24	2,875	90.3 (87.0–92.9)		<0.001	81.8
RFA	12	1,686	91.8 (87.2–94.9)		<0.001	85.6
RT	12	1,189	89.0 (83.6–92.7)	0.333	<0.001	79.7
Two-year OS (HCC)
All	22	2,802	77.2 (71.4–82.2)		<0.001	90.6
RFA	11	1,648	77.7 (70.7–83.4)		<0.001	88.2
RT	11	1,154	76.0 (64.4–84.7)	0.775	<0.001	92.7
Three-year OS (HCC)
All	18	2,518	67.5 (60.3–74.0)		<0.001	91.1
RFA	9	1,449	68.5 (59.3–76.5)		<0.001	90.7
RT	9	1,069	65.9 (53.7–76.3)	0.718	<0.001	92.4
One-year OS (CRC mets)
All	8	629	86.6 (77.7–92.3)		<0.001	86.0
RFA	4	433	88.2 (77.9–94.0)		0.001	81.8
RT	4	196	82.7 (61.6–93.4)	0.507	0.001	81.1
Two-year OS (CRC mets)
All	8	629	62.2 (54.0–69.8)		<0.001	80.8
RFA	4	433	66.4 (50.9–79.0)		<0.001	88.2
RT	4	196	60.6 (50.7–69.6)	0.517	0.195	36.3
Three-year OS (CRC mets)
All	8	629	49.9 (40.5–59.3)		<0.001	83.7
RFA	4	433	52.1 (41.1–62.8)		0.003	78.5
RT	4	196	43.6 (26.6–62.1)	0.444	0.002	79.5
Grade ≥3 complication
All	26	4,698	2.9 (1.9–4.4)		<0.001	72.5
RFA	13	3,415	2.9 (1.4–6.1)		<0.001	73.0
RT	13	1,283	2.8 (1.6–4.9)	0.952	<0.001	73.2

CRC, colorectal cancer; HCC, hepatocellular carcinoma; LC, local control; OS, overall survival; RFA, radiofrequency ablation; RT, radiotherapy.